weight loss drug

BAGSVÆRD, Denmark, May 22, 2026 Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human...

INDIANAPOLIS, May 21, 2026 Eli Lilly and Company announced positive topline results from its pivotal Phase 3 TRIUMPH-1 clinical...

INGELHEIM, GERMANY, April 28, 2026 Boehringer Ingelheim has announced positive Phase III results for its investigational dual agonist survodutide,...

INDIANAPOLIS, April 9, 2026 Eli Lilly and Company has announced the U.S. launch of Foundayo™ (orforglipron), a first-in-class oral...

INDIANAPOLIS, USA — April 1, 2026 In a landmark advancement in obesity treatment and metabolic disease management, Eli Lilly...

BAGSVÆRD, Denmark, March 19, 2026 Novo Nordisk A/S announced that the U.S. Food and Drug Administration (FDA) has approved...